Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio sull'Efficacia e Tollerabilità di Qualia in Perimenopausa: Uno Studio in Aperto a 3 Bracci

1 ottobre 2026 aggiornato da: Qualia Life Sciences

Qualia Perimenopause Studio di Efficacia e Tollerabilità: Uno Studio Aperto a 3 Bracci

This is an open-label, 3-arm clinical trial evaluating the short-term efficacy and tolerability of Qualia Perimenopause-a multi-ingredient dietary supplement formulated to support perimenopausal symptoms-in healthy women aged 40-55 who are symptomatic but not yet menopausal (menses within the past 12 months). Approximately 120 participants will be allocated across three parallel arms and will take 1 capsule once daily for 28 consecutive days. The primary outcome is between-group change from baseline to day 28 in menopause symptom burden measured by the total Menopause Rating Scale (MRS). Secondary outcomes include within- and between-group changes at days 14 and 28 in cognitive function (PROMIS Cognitive Function v2.0 - Short Form 8a), sleep disturbance (PROMIS), MRS subdomains (psychological, somato-vegetative, urogenital), overall MRS change, safety/tolerability (custom survey), and participant-reported product experience. All assessments are completed electronically at home at baseline, mid-intervention (day 14), and end-of-study (day 28), with a brief follow-up questionnaire; there are no in-person visits.

Panoramica dello studio

Descrizione dettagliata

Perimenopause is a transitional phase preceding menopause characterized by fluctuating ovarian hormone levels and variable cycle length, often accompanied by a constellation of symptoms spanning vasomotor disturbances, sleep disruption, cognitive and attentional changes, mood lability, somatic complaints, and urogenital discomfort. These symptoms can meaningfully impair quality of life, productivity, interpersonal functioning, and health-related well-being. Although menopausal hormone therapy is an established option for selected individuals, many women either do not elect or are not candidates for hormone-based interventions and seek nonhormonal approaches that address multiple symptom domains concurrently. In this context, multi-ingredient botanical formulations are of growing interest as supportive strategies designed to target the diverse and interrelated pathways implicated in perimenopausal symptomatology.

Qualia Perimenopause is a multi-botanical natural health product/dietary supplement formulated to support women during the perimenopausal transition. The formulation is intended to address common domains of symptom burden-including vasomotor, psychological, cognitive, and sleep-related complaints-through complementary mechanisms of action.

Study Design: This is an open-label, three-arm, parallel-group trial with stratified systematic allocation by baseline Menopause Rating Scale (MRS) total score. Participants will be stratified and assigned to one of three study arms in a 1:1:1 ratio. Study duration is 28 days of supplementation.

Participants will take one capsule once daily of their assigned formula for 28 consecutive days. All data are self-reported; assessments are completed electronically at home at baseline, mid-intervention (day 14), and end-of-study (day 28), with a brief follow-up questionnaire. Approximately 120 healthy female participants ages 40-55 with menopause symptoms but not yet in menopause (period within last 12 months) and MRS total score ≥ 5 will be enrolled.

Note on allocation (added September 2026): Participants were assigned to study arms by systematic allocation rather than by random allocation. Earlier versions of this record described the design as randomized. The Allocation field and the design descriptions were corrected to Non-Randomized to reflect the method actually used. No other aspect of the study design, conduct, or analysis changed.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

66

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • California
      • Carlsbad, California, Stati Uniti, 92008
        • Qualia Life Sciences

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 40 anni a 55 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion criteria:

  1. Provide voluntary, written, informed consent to participate in the study
  2. Agree to provide a valid cell phone number and are willing to receive communications through text
  3. Can read and write English
  4. Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly
  5. Willing to complete questionnaires, records, and diaries associated with the study
  6. Healthy female participants ages 40-55 with menopause symptoms but not yet in menopause (period within last 12 months)
  7. MRS total score ≥ 5 (preference given to higher score)

Exclusion criteria:

  1. Women who are pregnant, breastfeeding, or planning to become pregnant or start breastfeeding during the trial
  2. Known food intolerances/allergy to any ingredients in the product
  3. Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer
  4. Having had a significant cardiovascular event in the past 6 months
  5. Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines
  6. On immunosuppressive therapy
  7. Having had surgery within the past 6 weeks or upcoming planned surgery in the next few months
  8. Adults lacking capacity to consent
  9. Post-menopause (≥12 consecutive months without a period)
  10. Taking medications: hormone replacement therapy; oral contraceptives; selective estrogen receptor modulators/aromatase inhibitors (e.g., Tamoxifen); sedatives/anxiolytics; blood thinners; insulin

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Qualia Formula Perimenopausa A

Qualia Perimenopause is a multi-botanical natural health product/dietary supplement formulated to support women during the perimenopausal transition. The formulation is intended to address common domains of symptom burden-including vasomotor, psychological, cognitive, and sleep-related complaints-through complementary mechanisms of action. Participants receive one capsule once daily for 28 consecutive days. Three different formulations are being tested in this trial (Formula A, Formula B, and Formula C).

Sperimentale: Qualia Formula Perimenopausa B

Qualia Perimenopause is a multi-botanical natural health product/dietary supplement formulated to support women during the perimenopausal transition. The formulation is intended to address common domains of symptom burden-including vasomotor, psychological, cognitive, and sleep-related complaints-through complementary mechanisms of action. Participants receive one capsule once daily for 28 consecutive days. Three different formulations are being tested in this trial (Formula A, Formula B, and Formula C).

Sperimentale: Qualia Perimenopause Formula C

Qualia Perimenopause is a multi-botanical natural health product/dietary supplement formulated to support women during the perimenopausal transition. The formulation is intended to address common domains of symptom burden-including vasomotor, psychological, cognitive, and sleep-related complaints-through complementary mechanisms of action. Participants receive one capsule once daily for 28 consecutive days. Three different formulations are being tested in this trial (Formula A, Formula B, and Formula C).

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Menopause Rating Scale (MRS) - Total Score
Lasso di tempo: Day 28

Between-group change from baseline to Day 28 in menopause symptoms measured by the total Menopause Rating Scale (MRS) score. The MRS is an 11-item self-rating scale that measures the severity of menopausal symptoms with a total score range of 0-44.

Day 28

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
PROMIS Cognitive Function v2.0 - Short Form 8a
Lasso di tempo: Day 14, Day 28

Within- and between-group changes from baseline to Days 14 and 28 in cognitive function measured by PROMIS Cognitive Function v2.0 - Short Form 8a, an 8-item assessment of perceived cognitive abilities including mental acuity, concentration, and memory.

Day 14, Day 28
Safety and Tolerability Survey
Lasso di tempo: Day 14, Day 28

Within- and between-group changes from baseline to Days 14 and 28 in side effect profile using a custom Safety and Tolerability survey assessing symptoms including nausea, headache, mood changes, dizziness, bloating, itching, and sexual dysfunction.

Day 14, Day 28
PROMIS Sleep Disturbance - Short Form
Lasso di tempo: Day 14, Day 28

Within- and between-group changes from baseline to Days 14 and 28 in sleep measured by PROMIS Sleep Disturbance - Short Form, an 8-item assessment of sleep quality, restfulness, and disturbance severity.

Day 14, Day 28
MRS Psychological Subdomain
Lasso di tempo: Day 14, Day 28

Within- and between-group changes from baseline to Days 14 and 28 in the Psychological subdomain of the Menopause Rating Scale (items 4-7: depressive mood, irritability, anxiety, exhaustion).

Day 14, Day 28
MRS Somato-Vegetative Subdomain
Lasso di tempo: Day 14, Day 28

Within- and between-group changes from baseline to Days 14 and 28 in the Somato-vegetative subdomain of the Menopause Rating Scale (items 1-3, 11: hot flashes, heart discomfort, sleep problems, joint/muscle discomfort).

Day 14, Day 28
MRS Urogenital Subdomain
Lasso di tempo: Day 14, Day 28

Within- and between-group changes from baseline to Days 14 and 28 in the Urogenital subdomain of the Menopause Rating Scale (items 8-10: sexual problems, bladder problems, vaginal dryness).

Day 14, Day 28
Follow-up Questionnaire
Lasso di tempo: Day 33 (5-7 days after final dose)

Participant thoughts and feelings about the product assessed via a Follow-up Questionnaire administered 5-7 days after the final dose. Evaluates overall experience, product rating, purchase interest, and detailed product experience description.

Day 33 (5-7 days after final dose)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

16 marzo 2026

Completamento primario (Effettivo)

22 aprile 2026

Completamento dello studio (Effettivo)

27 aprile 2026

Date di iscrizione allo studio

Primo inviato

15 gennaio 2026

Primo inviato che soddisfa i criteri di controllo qualità

15 gennaio 2026

Primo Inserito (Effettivo)

23 gennaio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

1 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • QLS-021

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi